[Click eStock] "S-Biomedics, Increased Potential for Global Technology Export"

Hanyang Securities analyzed on the 19th that S-Biomedics has a high possibility of global technology export and that the current price decline without any reason is an attractive opportunity.

Oh Byung-yong, a researcher at Hanyang Securities, stated in a report on the same day, “S-Biomedics disclosed the 12-month observation results of the high-dose patient group (n=3) for the Parkinson’s disease new drug ‘TED-A9’ on the 12th,” adding, “Although the sample size is small, it shows an effect where patients with severe, previously bedridden, incurable Parkinson’s disease were able to stand up and move.”

Researcher Oh explained, “Large-scale technology export (L/O) contracts for domestic drugs have occurred when the drug and mechanism/form are similar to those of big pharma, and the initial data are comparable or even superior. The company has produced overwhelmingly best-in-class global data within its category, and there is a good comparator called ‘Vemdanefrocel,’” adding, “According to the company, many global pharmaceutical companies have been waiting for this high-dose data, so we judge that the possibility of a global L/O is high.”

Expectations are also high for the enforcement of the revised Advanced Regenerative Medicine and Advanced Biopharmaceuticals Act (ARMA). He said, “The revised ARMA, which will be enforced on February 21, 2025, allows clinical-stage drugs to be used for treatment purposes with payment from patients,” adding, “Although it is limited to serious rare and intractable diseases without treatments and requires completion of small-scale advanced biopharmaceutical clinical trials, it seems certain that the company will be the biggest beneficiary.”

Furthermore, he noted, “Although S-Biomedics announced excellent clinical trial results, its stock price has fallen by 48.8%, and its market capitalization has dropped to 217.1 billion KRW,” adding, “Considering that ‘Vemdanefrocel’ is worth trillions of KRW, that commercialization is very close due to ARMA, and that the stock price has sharply declined without any particular reason, the current stock price is attractive.”